OC07.02: Multicentre screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation: comparison to NICE guidelines and ACOG recommendations
N. O’Gorman(Harris Birthright Research Centre for Fetal Medicine), K. H. Nicolaides(Harris Birthright Research Centre for Fetal Medicine), Daniel L. Rolnik(Monash Health), Argyro Syngelaki(University College Hospital), N. Karagiotis(Harris Birthright Research Centre for Fetal Medicine), Leo L. M. Poon(Hong Kong Science and Technology Parks Corporation), F. Carbone(Ospedale Maggiore), Andrea Pazos(Instituto de Investigación Biosanitaria de Granada), G. Papaioannou(University General Hospital Attikon), D. Wright(Yale University), W. Plasencia(Hospiten Group), Alexander Frick(Harris Birthright Research Centre for Fetal Medicine), M. Fiolna(Medway Maritime Hospital), S. Mastrodima(Harris Birthright Research Centre for Fetal Medicine), V. Dütemeyer(Medizinische Hochschule Hannover), M. De Alvarado(Homerton University Hospital), C. de Paco Matallana(Instituto de Salud Carlos III)
Cited by 1
Related Papers
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
Observed to expected lung area to head circumference ratio in the prediction of survival in fetuses with isolated diaphragmatic hernia
|Ultrasound in Obstetrics and Gynecology|2007|623
ASPRE trial: performance of screening for preterm pre‐eclampsia
|Ultrasound in Obstetrics and Gynecology|2017|455
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
|Cell Reports|2020|450